Key result
The ARXAR model yielded a baroreflex gain of 5.4 +/- 3.3 ms/mmHg, comparable to the phenylephrine test (6.4 +/- 4.7 ms/mmHg) and avoiding overestimation by traditional noninvasive methods.
Why the study?
Does the ARXAR model provide a more accurate noninvasive estimation of baroreflex sensitivity compared to traditional methods in patients with recent myocardial infarction?
Cross-Sectional (n=30)
Does the ARXAR model provide a more accurate noninvasive estimation of baroreflex sensitivity compared to traditional methods in patients with recent myocardial infarction?
Absolute Event Rate: 5.4% vs 6.4%
The ARXAR model provides a noninvasive estimate of baroreflex sensitivity that closely agrees with the invasive phenylephrine test in patients with recent myocardial infarction.
ARXAR may support noninvasive BRS estimation in recent MI; leaves open its clinical utility pending prospective validation.
Spectral and cross-spectral analysis of R-R interval and systolic arterial pressure (SAP) spontaneous fluctuations have been proposed for noninvasive evaluation of baroreflex sensitivity (BRS). However, results are not in good agreement with clinical measurements. In this study, a bivariate parametric autoregressive model with exogenous input (ARXAR model), able to divide the R-R variability into SAP-related and -unrelated parts, was used to quantify the gain (alpha(ARXAR)) of the baroreflex regulatory mechanism. For performance assessing, two traditional noninvasive methods based on frequency domain analysis [spectral, baroreflex gain by autogressive model (alpha(AR)); cross-spectral, baroreflex gain by bivariate autoregressive model (alpha(2AR))] and one based on the time domain [baroreflex gain by sequence analysis (alpha(SEQ))] were considered and compared with the baroreflex gain by phenylephrine test (alpha(PHE)). The BRS evaluation was performed on 30 patients (61 +/- 10 yr) with recent (10 +/- 3 days) myocardial infarction. The ARXAR model allowed dividing the R-R variability (950 +/- 1,099 ms(2)) into SAP-related (256 +/- 418 ms(2)) and SAP-unrelated (694 +/- 728 ms(2)) parts. alpha(AR) (12.2 +/- 6.1 ms/mmHg) and alpha(2AR) (8.9 +/- 5.6 ms/mmHg) as well as alpha(SEQ) (12.6 +/- 7.1 ms/mmHg) overestimated BRS assessed by alpha(PHE) (6.4 +/- 4.7 ms/mmHg), whereas the ARXAR index gave a comparable value (alpha(ARXAR) = 5.4 +/- 3.3 ms/mmHg). All noninvasive methods were significantly correlated to alpha(PHE) (alpha(ARXAR) and alpha(SEQ) were more correlated than the other indexes). Thus the baroreflex gain obtained describing the causal dependence of R-R interval on SAP showed a good agreement with alpha(PHE) and may provide additional information regarding the gain estimation in the frequency domain.
No takes yet. Share an insight, caveat, or question.
Nollo et al. (2001) conducted a cross-sectional in recent myocardial infarction (n=30). ARXAR model for baroreflex gain assessment vs. Traditional noninvasive methods and phenylephrine test was evaluated on Baroreflex gain (BRS). The ARXAR model yielded a baroreflex gain of 5.4 +/- 3.3 ms/mmHg, comparable to the phenylephrine test (6.4 +/- 4.7 ms/mmHg) and avoiding overestimation by traditional noninvasive methods.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: